Sandoz receives Canada approval for generic Ozempic
Sandoz Group said Canada’s drug regulator has approved its generic version of Novo Nordisk’s Ozempic, supporting its GLP-1 portfolio plans.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP — 1 medicine
Sandoz Group AG / Key word(s): Regulatory Approval Sandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP-1 medicine 18-Sep-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of th